The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity

BACKGROUND: New antithrombotic therapies with less effect on bleeding are needed for coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque–mediated thrombus formation. However, it is associated with increased bleeding, possibly due to non–Btk‐mediated effects. Btk‐defici...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Christopher W., Harbi, Maan H., Garcia‐Quintanilla, Lourdes, Rookes, Kieran, Brown, Helena, Poulter, Natalie S., Watson, Steve P., Nicolson, Phillip L. R., Thomas, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827830/
https://www.ncbi.nlm.nih.gov/pubmed/36239466
http://dx.doi.org/10.1111/jth.15899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827830/
https://www.ncbi.nlm.nih.gov/pubmed/36239466
http://dx.doi.org/10.1111/jth.15899

Ejemplares similares